<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341389</url>
  </required_header>
  <id_info>
    <org_study_id>JSVCT089</org_study_id>
    <nct_id>NCT04341389</nct_id>
  </id_info>
  <brief_title>A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)</brief_title>
  <acronym>CTII-nCoV</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hubei Provincial Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in
      healthy adults above 18 years of age. This clinical trial is designed to evaluate the
      immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of
      SARS-CoV-2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in
      healthy adults above 18 years of age,inclusive, who meet all eligibility criteria. This
      clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which
      encodes for a full-length spike (S) protein of SARS-CoV-2. 500 subjects will be enrolled, 250
      subjects in middle-dose vaccine group, 125 subjects in low-dose and placebo group,
      respectively. Immunogenicity will be tested on days 0, 14, 28 and 6 months after vaccination
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 12, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse reactions</measure>
    <time_frame>0-14 days post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti SARS-CoV-2 S IgG antibody response(ELISA)</measure>
    <time_frame>28 days post vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody response to SARS-CoV-2</measure>
    <time_frame>28 days post vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>0-28 days post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse reaction</measure>
    <time_frame>0-6 months post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti SARS-CoV-2 S IgG antibody response(ELISA)</measure>
    <time_frame>0, 14 days and 6 months post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody response to SARS-CoV-2</measure>
    <time_frame>0 and 6 months post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody response to Ad5-vector</measure>
    <time_frame>0, 28 days and 6 months post vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IFN-γ ELISpot responses to SARS-CoV-2 spike protein</measure>
    <time_frame>0 and 28 days post vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1×10^11vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5×10^10vp of Ad5-nCoV administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Ad5-nCoV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 60 years.

          -  Able to understand the content of informed consent and willing to sign the informed
             consent

          -  Able and willing to complete all the secluded study process during the whole 6 months
             study follow-up period.

          -  Negative in HIV diagnostic test.

          -  Negative in serum antibodies (IgG and IgM) screening of COVID-19.

          -  Axillary temperature ≤37.0°C.

          -  The BMI index is 18.5-30.0.

          -  General good health as established by medical history and physical examination.

        Exclusion Criteria:

          -  Family history of seizure, epilepsy, brain or mental disease

          -  Subject allergic to any component of the investigational vaccine, or a more severe
             allergic reaction and history of allergies in the past.

          -  Woman who is pregnant, breast-feeding or positive in β-HCG (human chorionic
             gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during
             the next 6 months

          -  Any acute fever disease or infections.

          -  History of SARS

          -  Major congenital defects or not well-controlled chronic illness, such as asthma,
             diabetes, or thyroid disease.

          -  Serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial
             infarction, severe hypertension without controllable drugs, etc.

          -  Hereditary angioneurotic edema or acquired angioneurotic edema

          -  Urticaria in last one year

          -  No spleen or functional spleen.

          -  Platelet disorder or other bleeding disorder may cause injection contraindication

          -  Faint at the sight of needles.

          -  Prior administration of immunodepressant or corticosteroids, antianaphylaxis
             treatment, cytotoxic treatment in last 6 months.

          -  Prior administration of blood products in last 4 months

          -  Prior administration of other research medicines in last 1 month

          -  Prior administration of attenuated vaccine in last 1 month

          -  Prior administration of inactivated vaccine in last 14 days

          -  Current anti-tuberculosis prophylaxis or therapy

          -  According to the judgement of investigator,various medical, psychological, social or
             other conditions, those could affect the subjects to sign informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengcai Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Province Centers of Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hubei Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 vaccine</keyword>
  <keyword>Ad5-nCoV</keyword>
  <keyword>SARS-CoV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

